Dapagliflozin Modulates the Gut Microbiota in Type 2 Diabetic Rats Model

The gut microbiota is recognized as a major modulator of metabolic disorders such as type 2 diabetes. Dapagliflozin, sodium glucose cotransporter 2 inhibitor (SGLT2i), enhances renal glucose excretion to lower blood glucose levels. The aim of the study was to determine the effects of dapagliflozin on gut microbiota type 2 diabetic rat models.Four-week-old male Sprague Dawley rats (n=24) were fed high-fat diet (HFD) for 8 weeks, and then followed by a single dose of injection of STZ (30mg/kg, ip). They were randomly divided into three groups (n=8). Each group received intragastric infusion of normal saline (2ml, 0.9%) or metformin (215.15mg/kg/day) or dapagliflozin (1mg/kg/day) for 4 weeks. Fecal samples were collected to access microbiomes by 16S ribosomal RNA gene sequencing.